system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Cisplatin, Doxorubicin, Female, Follow-Up Studies, Humans, Liposomes, Male, Mesothelioma, Middle Aged, Neoplasm Staging, Pharmaceutical Vehicles, Pleural Neoplasms, Prognosis, Radiopharmaceuticals, Survival Analysis, Technetium, Tissue Distribution, Tumor Burden.
user
Is high liposomal doxorubicin tumour tissue distribution , as determined by radiopharmaceutical labelling with ( 99m ) Tc-LD , associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin? Context: There are currently no available biomarkers for advanced pleural mesothelioma that determine which patients could benefit from a specific chemotherapy regimen. Based on the results of a previously published phase II study, we associated the (99m)Technetium-labelled liposomal doxorubicin ((99m)Tc-LD) uptake value (75 % cut-off) with the response rate, progression-free survival and overall survival of patients treated with a combination of liposomal doxorubicin and cisplatin. Patients with tumours exhibiting increased (99m)Tc-LD uptake showed better response rates, progression-free survival and overall survival than those exhibiting lower uptake 73.3 versus 15 % (p < 0.001); 6.9 versus 3.2 months (p = 0.033) and 23 versus 6.6 months (p = 0.001), respectively.
assistant
(99m)Tc-DL uptake in tumour tissue could define a set of patients who would benefit from this chemotherapy regimen. Final Decision: yes